{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:32:07Z","timestamp":1790526727130,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.04.004","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"285-294","source":"Crossref","is-referenced-by-count":16,"title":["CML: a model for targeted therapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Daniela","family":"Cilloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.04.004_bib1","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"32","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.04.004_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosome breakpoint are clustered within a limited region, bcr, on chromosome 22","volume":"33","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib3","first-page":"6649","article-title":"Induction of chronic myelogenous leukemia in mice by 210 bcr-abl gene of the Philadelphia chromosome","volume":"87","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.04.004_bib4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/j.1460-2075.1990.tb08212.x","article-title":"Bcr-Abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice","volume":"9","author":"Elefanty","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.beha.2009.04.004_bib5","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.04.004_bib6","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like disease in mice receiving p210bcr-abl-transformed bone marrow","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.beha.2009.04.004_bib8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.04.004_bib9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2013advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.004_bib10","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib11","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2009.04.004_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2009.04.004_bib13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.04.004_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s004390050547","article-title":"Localisation and distance between ABL and BCR genes in interphase nuclei of bone marrow cells of control donors and patients with chronic myeloid leukaemia","volume":"100","author":"Lukasova","year":"1997","journal-title":"Hum Genet"},{"key":"10.1016\/j.beha.2009.04.004_bib16","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood.V93.4.1197","article-title":"The nuclear topography of ABL, BCR, PML and RAR genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation","volume":"93","author":"Neves","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib17","doi-asserted-by":"crossref","first-page":"9882","DOI":"10.1073\/pnas.152171299","article-title":"A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of Philadelphia chromosome","volume":"99","author":"Saglio","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.04.004_bib18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.leukres.2007.01.022","article-title":"Acute myeloid leukaemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities","volume":"31","author":"Pawarode","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2009.04.004_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V58.1.158.158","article-title":"Evidence for a multistep pathogenesis of chronic myelogenous leukemia","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib20","first-page":"1163","article-title":"Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia","volume":"7","author":"Raskind","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.004_bib21","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.leu.2402848","article-title":"Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate","volume":"17","author":"O'Dwyer","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.004_bib23","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib24","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.04.004_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.004_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0092-8674(91)90148-R","article-title":"BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner","volume":"66","author":"Pendergast","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia \u2013 signaling pathways of initiation and transformation","volume":"118","author":"Melo","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.beha.2009.04.004_bib29","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/sj.onc.1201400","article-title":"The BCR-ABL tyrosine kinase activates mitotic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells","volume":"15","author":"Cortez","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2009.04.004_bib30","first-page":"899","article-title":"Constitutive phosphorylation of Shc proteins in human tumors","volume":"11","author":"Pelicci","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2009.04.004_bib31","first-page":"839","article-title":"The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR\/ABL and p210BCR\/ABL to the phosphatidylinositol\u20133 \u00a2 kinase pathway","volume":"12","author":"Sattler","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2009.04.004_bib32","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.04.004_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.181.1.307","article-title":"Genetic requirement for RAS in the trasformation of fibroblasts and hematopoietic cells by the BCR-ABL oncogene","volume":"181","author":"Sawyers","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2009.04.004_bib34","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2009.04.004_bib35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2009.04.004_bib36","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.11.2.1107","article-title":"Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants","volume":"11","author":"Varticovski","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.beha.2009.04.004_bib37","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/385544a0","article-title":"Suppression of c-Myc induced apoptosis by Ras signalling through PI 3-kinase and PKB","volume":"385","author":"Kauffmann-Zeh","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.beha.2009.04.004_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib39","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI\u20133k\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.beha.2009.04.004_bib40","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood.V88.5.1542.1542","article-title":"PI 3-kinase activation in BCR\/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR\/abl","volume":"88","author":"Jain","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(00)81883-8","article-title":"PI3K: downstream AKT blocks apoptosis","volume":"88","author":"Franke","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABl oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib43","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","article-title":"Jak2 is involved in c-Myc induction by Bcr-Abl","volume":"17","author":"Xie","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2009.04.004_bib44","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V85.12.3636.bloodjournal85123636","article-title":"Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages","volume":"85","author":"Bhatia","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib45","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1172\/JCI115543","article-title":"Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukaemia progenitor cells","volume":"88","author":"Upadhyaya","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2009.04.004_bib46","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/328342a0","article-title":"Altered adhesive interactions with marrow stroma of haemopoietic progenitor cells in chronic myeloid leukemia","volume":"328","author":"Gordon","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.beha.2009.04.004_bib47","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","article-title":"BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors","volume":"111","author":"Copland","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib48","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1038\/sj.onc.1206817","article-title":"Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression","volume":"22","author":"Uematsu","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2009.04.004_bib49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.004_bib50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ng791","article-title":"BCR-ABL suppresses C\/EBPalpha expression through inhibitory action of hnRNP E2","volume":"30","author":"Perrotti","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2009.04.004_bib51","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib52","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib53","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib54","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.004_bib55","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.004_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.004_bib57","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukaemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib58","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukaemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib59","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib60","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.004_bib61","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.004_bib62","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.04.004_bib63","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571","volume":"277","author":"Corbin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2009.04.004_bib64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib65","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2009.04.004_bib66","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2004.03.012","article-title":"Clonal evolution in chronic myelogenous leukaemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.beha.2009.04.004_bib67","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood-2007-02-074252","article-title":"German Chronic Myelogenous Leukemia (CML) Study Group. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia","volume":"110","author":"Kreil","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib68","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood.V97.7.2084","article-title":"BCR-ABL down-regulates the DNA repair protein DNA-PKcs","volume":"97","author":"Deutsch","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib69","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2403735","article-title":"Identification of genes potentially involved in disease transformation of CML","volume":"19","author":"Janssen","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.004_bib70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukaemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2009.04.004_bib71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2009.04.004_bib72","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.beha.2009.04.004_bib73","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.04.004_bib74","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib75","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome- positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.004_bib76","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is effective in patients chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.004_bib77","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib","volume":"105","author":"O'Hare","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.04.004_bib78","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny","volume":"105","author":"Elrick","year":"2005","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169260900022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169260900022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:59:10Z","timestamp":1590281950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169260900022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S152169260900022X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.04.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}